Kisqali Phase 3 Trial Meets Primary Endpoint for Patients Wi

Ribociclib plus endocrine therapy demonstrates a reduction in the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Related Keywords

Ribociclib Kisqali , Dennis Slamon , Shreeram Aradhye , Translational Research In Oncology , Global Drug Development , Novartis , University Of California Los Angeles , Data Monitoring Committee , Independent Data Monitoring Committee , Los Angeles , Translational Research , Practice Guidelines ,